Form 8-K · Current report
Marsh McLennan 8-K, filed Oct 15, 2026
- Filed
- CIK
- 0000062709
- Accession no.
- 0000062709-26-000256
Summary
Marsh reported third-quarter 2026 revenue of $6.9 billion, up 8% on a GAAP basis and 5% on an underlying basis, with GAAP EPS of $1.69 and adjusted EPS up 10% to $2.03. CEO John Doyle said the company completed its brand transition from Marsh McLennan to Marsh and made significant progress on its Thrive program.
Key points
- Third-quarter 2026 consolidated revenue was $6.9 billion, up 8% GAAP and 5% underlying year over year.
- Third-quarter GAAP operating income rose 4% to $1.2 billion, while adjusted operating income rose 6% to $1.5 billion.
- Third-quarter GAAP EPS was $1.69, and adjusted EPS increased 10% to $2.03.
- The company repurchased about 2.7 million shares for $500 million in the quarter and repaid 550 million of Euro-denominated senior notes that matured in September.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On October 15, 2026, Marsh & McLennan Companies, Inc. issued a press release reporting financial results for the third quarter ended September 30, 2026, and announcing that a conference call to discuss such results will be held at 8:30 a.m. Eastern time on October 15, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. For purposes of Section 18 of the Securities Exchange Act of 1934, the press release is deemed furnished not filed. Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press release issued by Marsh & McLennan Companies, Inc. on October 15, 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.